Myofibroblasts proliferation of idiopathic and collagen vascular disorders associated nonspecific interstitial pneumonia. by Niimi, Takashi et al.
Acta Medica Okayama
Volume 57, Issue 1 2003 Article 5
FEBRUARY 2003
Myofibroblasts proliferation of idiopathic and
collagen vascular disorders associated
nonspecific interstitial pneumonia.
Takashi Niimi∗ Takeo Yoshinouchi† Yuji Ohtsuki‡
Jiro Fujita∗∗ Shigeki Sato†† Yoshiki Sugiura‡‡
Kazutaka Ohta§ Motoharu Kajiura¶ Ryuzo Ueda‖
∗Nagoya City University,
†Higashi Municipal Hospital of Nagoya,
‡Kochi Medical School,
∗∗Kagawa Medical University,
††Nagoya City University,
‡‡Nagoya City University,
§Higashi Municipal Hospital of Nagoya,
¶Higashi Municipal Hospital of Nagoya,
‖Nagoya City University,
Copyright c©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
Myofibroblasts proliferation of idiopathic and
collagen vascular disorders associated
nonspecific interstitial pneumonia.∗
Takashi Niimi, Takeo Yoshinouchi, Yuji Ohtsuki, Jiro Fujita, Shigeki Sato,
Yoshiki Sugiura, Kazutaka Ohta, Motoharu Kajiura, and Ryuzo Ueda
Abstract
Nonspecific interstitial pneumonia (NSIP) has been recognized as a separate histological clas-
sification of interstitial lung disease. Similar features are found not only in idiopathic NSIP, but
also in NSIP associated with collagen vascular disorder (CVD-NSIP). We examined the clinical
symptoms, laboratory findings, and prognosis of 13 cases of idiopathic NSIP and 11 cases of CVD-
NSIP. Immunohistochemical staining was performed using the streptavidin/biotin/peroxidase method
with anti-alpha-smooth muscle actin antibody. No differences in the distribution of clinical fea-
tures, laboratory findings, and prognosis were observed between idiopathic NSIP and CVD-NSIP.
In immunohistochemical staining of the fibrosing areas, myofibroblasts were observed in 7 of 13
idiopathic NSIP cases, but in 10 of 11 CVD-NSIP cases. With regards to intra-alveolar organiza-
tion, myofibroblasts were observed in all 10 CVD-NSIP cases, but they were observed in only 2 of
9 idiopathic NSIP cases. We found a significantly higher myofibroblast proliferation in the intra-
alveolar organization of CVD-NSIP compared to idiopathic NSIP. Clinically, idiopathic NSIP and
CVD-NSIP are similar, but are pathologically different.
KEYWORDS: interstitial pneumonia, nonspecific interstitial pneumonia, myofibroblast, collagen
vascular disorder
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Nonspeciﬁc interstitial pneumonia (NSIP) has been recognized as a separate histological classiﬁcation of interstitial lung disease. Similar features are found not only in idiopathic NSIP, but also in NSIP associated with collagen vascular disorder (CVD-NSIP). We examined the clinical symptoms, laboratory ﬁndings, and prognosis of 13 cases of idiopathic NSIP and 11 cases of CVD-NSIP. Immunohistochemical staining was performed using the streptavidin/biotin/peroxidase method with anti-α-smooth muscle actin antibody. No diﬀerences in the distribution of clinical features, laboratory ﬁndings, and prognosis were observed between idiopathic NSIP and CVD-
NSIP. In immunohistochemical staining of the ﬁbrosing areas, myoﬁbroblasts were observed in 7 of 13 idiopathic NSIP cases, but in 10 of 11 CVD-NSIP cases. With regards to intra-alveolar organization, myoﬁbroblasts were observed in all 10 CVD-NSIP cases, but they were observed in only 2 of 9 idiopathic NSIP cases. We found a signiﬁcantly higher myoﬁbroblast proliferation in the intra-alveolar organization of CVD-NSIP compared to idiopathic NSIP. Clinically, idiopathic NSIP and CVD-NSIP are similar, but are pathologically diﬀerent.
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I diopathic interstitial pneumonia (IIP) has been classiﬁed into the following pathological types:
usual interstitial pneumonia (UIP), desquamative inter-
stitial pneumonia (DIP), acute interstitial pneumonia
(DAD), bronchiolitis obliterans organizing pneumonia
(BOOP), respiratory bronchiolitis interstitial lung disease
(RB-ILD), and nonspeciﬁc interstitial pneumonia(NSIP)
［1, 2］. In 1994, Katzenstein and Fiorelli et al. reported on the clinical and pathological features of NSIP, the latter being characterized by various degrees of interstitial inﬂammatory or ﬁbrosing processes that appeared tempo-
rally uniform within each case［2］. Frequently, BOOP and the intra-alveolar accumulation of macrophages are observed, but honey-combing is rarely present. Clinical-
ly, the condition often aﬀects middle-aged females, who present with coughing, a low-grade fever, and dyspnea for several months, but who respond well to corticoster-
oid therapy and have a good prognosis［3, 4］. Recent
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studies have also demonstrated that the clinical features of NSIP, compared with UIP, generally improve with corticosteroid therapy, and that patients with the disease have a good prognosis［4-9］. Similar pathological ﬁndings may be exhibited not only by idiopathic interstitial pneumonia, but also interstitial pneumonia associated with collagen vascular disease［3］. However, to our knowl-
edge, there have been no studies comparing idiopathic NSIP and NSIP associated with collagen vascular dis-
order(CVD-NSIP).
Myoﬁbroblasts are cells which have ultrastructural features intermediate in form to those of ﬁbroblasts and smooth muscle cells. Myoﬁbroblasts vary in the types of contractile and intermediate ﬁlaments they express. They have been suggested to play a role in wound contraction and in the retractile phenomena observed during ﬁbrotic diseases. It has been reported that many myoﬁbroblasts were observed in both the intra-alveolar organization and the ﬁbroblastic foci of UIP［10-14］. In our previous study, the appearance of myoﬁbroblasts diﬀered between idiopathic UIP and the UIP of rheumatoid arthritis-
associated interstitial pneumonia(RA-IP)［14］. In RA-
IP, myoﬁbroblasts were widely observed, together with the pathological patterns of honeycombing, UIP and bronchiolitis obliterans organizing pneumonia (BOOP),
whereas in idiopathic pulmonary ﬁbrosis(IPF)cases, the ﬁbrosis was mainly characterized by a lack of myoﬁbroblasts［14］. This suggests that IPF and RA-IP could be diﬀerentiated from each other on the basis of myoﬁbroblast proliferation. To investigate whether diﬀerences exist between idiopathic NSIP and CVD-
NSIP, we compared the clinical features of idiopathic NSIP and CVD-NSIP, and also investigated the im-
munohistochemical staining of myoﬁbroblasts in the 2 groups.
Materials and Methods
 
Thirteen idiopathic NSIP and 11 CVD-NSIP patients, all diagnosed as NSIP by open lung biopsy from 1993 to 1998, were studied. Of the CVD-NSIP cases, 7 were suﬀering from polymyositis
(PM) or dermatomyositis (DM), 2 from progressive systemic scleroderm (PSS), and 2 from the Sjogren syndrome(SjS). The idiopathic NSIP patients consisted of 8 males and 5 females, with a mean age of 64.3±7.2
(mean±SD) years. All CVD-NSIP patients were females with a mean age of 54.5±9.9 years. Six of the
 
idiopathic NSIP and none of the CVD-NSIP patients were smokers. All pathological specimens were analyzed in accordance with the NSIP criteria described by Katzenstein and Fiorelli［3］.
Peripheral blood samples were obtained before breakfast, and the white blood cells
(WBC)were assessed. After centrifugation at 1000 g for 10 min, the serum was stored at－70°C, and lactate dehydrogenase(LDH)was then measured. Arterial blood samples were analyzed for PaO?and PaCO?, and the bronchoalveolar lavage ﬂuid(BALF), cell diﬀerentiation count, and OKT4/8 ratio were evaluated. As a pulmo-
nary function test, the percentage of predicted vital capacity ( VC) and percentage of carbon monoxide diﬀusing capacity of the lung ( DLCO) were also measured.
To assess the therapeutic response, 3 categories based on those established by Nagai et al. were deﬁned:
condition improved, condition unchanged, and condition worsened (radiographically and functionally). Clearance of≧20  in shadow areas on chest radiographs and changes of＋20  in the measured values of the pulmo-
nary functions were evaluated as the patients’conditions improved. An increase of≧20 or more in the shadow areas, and changes of－20  in the measured values of the pulmonary functions, were evaluated as patients’
conditions worsened［5］.
Specimens from the 13 idiopathic NSIP cases and 11 CVD-NSIP cases studied were examined by immunohistochemical staining. Lung biopsy specimens were ﬁxed in 10 neutral buﬀered formalin solution, cut into slices, embed-
ded in paraﬃn, and sectioned at 5μm for histological evaluation. Immunohistochemical staining was performed using the streptavidin/biotin/peroxidase method with anti-vimentin, anti-desmin (Dakopatts, Glostrup, Den-
mark)and antiα-smooth muscle actin(α-SMA)antibody
(Bio Marker, Rehovot, Israel) (Figs. 1A, 1B). The presence of myoﬁbroblasts within the ﬁbrosing area and intra-alveolar lesions was determined according to im-
munohistochemical staining, i.e., myoﬁbroblasts are vimentin-positive,α-SMA-positive, and desmin-negative as reported previously［14, 15］. The distribution of myoﬁbroblasts in each section was evaluated according to a 4-point scale:3＝many myoﬁbroblastic foci, 2＝some myoﬁbroblastic foci in parts, 1＝ only focal myoﬁbroblastic foci, 0＝no myoﬁbroblastic foci. Smooth
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 muscle cells in the perivascular areas,which were positive forα-SMA, were excluded from the evaluation.
Comparison of the clini-
cal features, laboratory ﬁndings, and BALF between the idiopathic NSIP and CVD-NSIP was performed using the Students-t or chi-square tests. The relationship between the presence of myoﬁbroblasts and the response to therapy were also analyzed with Fisher’s exact test.
Kaplan-Meier survival curves were plotted, and the survival curves were compared by the log rank test. A P value of＜0.05 was considered signiﬁcant.
Results
 
A higher percentage of CVD-NSIP cases were females, and they were also younger on average than the idiopathic NSIP cases. Smokers were more numerous among cases of idiopathic NSIP. These diﬀerences were statistically signiﬁcant. Regarding clinical symptoms, in idiopathic NSIP, fever, cough, and dyspnea were found in 3 of 13,
10 of 13, and 10 of 13 cases, respectively, and in CVD-NSIP, in 5 of 11, 8 of 13, and 9 of 13 cases. No signiﬁcant diﬀerences in the distribution of these symp-
toms were observed. A comparison of the laboratory ﬁndings (WBC, LDH, VC, DLCO, PaO?,
PaCO?), also revealed no diﬀerences between idiopathic NSIP and CVD-NSIP. In BALF, increased lymphocytes were observed in both groups, without,
however, signiﬁcant variation(Table 1).
Of the 13 idiopathic NSIP patients, corticosteroids were administered to 11,
and an immunosuppressive agent plus corticosteroids to 2.
Of the 11 CVD-NSIP patients, 7 cases received cortico-
steroids, and 4 an immunosuppressive agent plus cor-
ticosteroids. In the 13 idiopathic NSIP cases receiving therapy, 11 patients improved, 1 case died because of respiratory failure, and 1 case remained alive with no response. In the 11 CVD-NSIP cases receiving therapy,
7 cases improved, 2 cases died of respiratory failure, and 2 cases survived with no response (Table 1). No signiﬁcant diﬀerence in survival was evident between the idiopathic NSIP and CVD-NSIP groups (data not shown).
In the im-
munostaining of the ﬁbrosing areas of the 13 idiopathic NSIP cases, myoﬁbroblasts were observed in 7 cases,
and not in the remaining 6 cases, whereas in the 11 CVD-NSIP cases, myoﬁbroblasts were observed in 10 cases, and not in the remaining case. We found a signiﬁcant increase of myoﬁbroblasts in CVD-NSIP compared with idiopathic NSIP (P＜0.05)(Table 2).
Intra-alveolar organization was found in 9 of the 13 idiopathic NSIP cases evaluated. Of the 9 idiopathic NSIP cases with intra-alveolar organization,
myoﬁbroblasts were observed in 2 cases, but not in the remaining 7. Of the 11 CVD-NSIP cases evaluated,
intra-alveolar organization was found in 10 cases, all of which contained myoﬁbroblasts (Figs. 1A, 1B). The diﬀerence in the appearance of myoﬁbroblasts in the areas
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Fig.1 (A)Negative immunoreactivity of intra-alveolar organization with anti-αsmooth muscle actin antibody in idiopathic NSIP(×220). (B)
Positive reaction of myoﬁbroblasts with anti-αsmooth muscle actin antibody in intra-alveolar organization of CVD-NSIP(×220).
35
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 of intra-alveolar organization was statistically signiﬁcant
(P＜0.001)(Table 3). In the 9 idiopathic NSIP cases with intra-alveolar organization, the 2 myoﬁbroblast positive cases did not improve after therapy, but the 7 myoﬁbroblast negative cases showed improvement. In the 10 intra-alveolar organization positive CVD-NSIP cases,
6 cases improved after therapy, but 4 cases showed no improvement after therapy.
Discussion
 
In our series of 24 cases of NSIP, 18(75 )respond-
ed well to corticosteroid therapy with a good overall prognosis. However, NSIP is not a separate disease entity, and includes interstitial pneumonia associated collagen vascular disease in 16  of the cases, and various other diseases as reported by Katzenstein［2］.
The present comparative study of idiopathic NSIP and CVD-NSIP, however, revealed no signiﬁcant diﬀerences
 
Table 1  Patients characteristics
 
Case Age
/Sex
(yrs)
Diag-
nosis  
Myoﬁbroblasts Figrosing Intraalveolar Fever
 Coug-
hing 
Dysp-
nea 
WBC
(μl)
LDH
(w.u)
%VC
(%)
%DLCO
(%)
PaO?
(Torr)
PaCO?
(Torr)
BALF Ly(%) Treatment
 Res-
ponse
 
1  60 M  IIP  0  0 － － ＋ 5400 410 69.0  70.1  68.0  30.4  95  Steroid  I 2  60 M  IIP  2  2 － ＋ ＋ 8600 554 80.2  97.4  80.0  47.7  21  Steroid＋CPM  D 3  51 F  IIP  0  0 ＋ ＋ － 6300 239  39.2  74.9  41.6  36  Steroid  I 4  74 M  IIP  1  0 － － ＋ 10000 600 132.0 103.0  79.4  40.7  Steroid  I 5  66 M  IIP  0  0 ＋ ＋ ＋ 10900 441  57.2  30.2  3  Steroid  I 6  74 M  IIP  1  0 － － ＋ 5000 286  57.2  65.2  46.9  15  Steroid  I 7  52 F  IIP  2 － ＋ － 7500 487 85.7  56.7  88.0  38.3  20  Steroid  I 8  66 F  IIP  2  2 － ＋ － 7300 558 62.1  83.0  66.5  36.8  8  Steroid＋CPM  N 9  62 F  IIP  0 － ＋ ＋ 7000 492 54.9  60.2  52.9  41.0  80  Steroid  I 10  67 F  IIP  2 ＋ ＋ ＋ 10900 628  62.1  42.0  35.0  20  Steroid  I 11  69 M  IIP  0  0 － ＋ ＋ 4600 288 94.8 101.0  78.8  47.4  5  Steroid  I 12  67 M  IIP  0  0 － ＋ ＋ 9800 251  70.8  74.9  35.9  36  Steroid  I 13  69 M  IIP  2 － ＋ ＋ 5000 408 40.9  71.3  67.0  35.7  40  Steroid  I 14  40 F  DM  3  3 ＋ ＋ ＋ 2500 1582  Steroid＋CPM  D 15  55 F  DM  2  2 － － ＋ 9600 1068  73.2  68.0  35.4  Steroid＋CPM  I 16  44 F  DM  2  3 ＋ － ＋ 2700 460 57.7  86.3  84.3  33.8  21  Steroid＋CPM  D 17  69 F  DM  3  2 － － － 14500 860 104.0  76.5  73.2  45.4  Steroid  I 18  45 F  DM  1  1 － ＋ ＋ 10800 318  53.0  72.0  47.0  16  Steroid  I 19  55 F  DM  3  1 － ＋ ＋ 4100 254  62.1  72.0  38.0  Steroid  I 20  47 F  PM  0 － ＋ ＋ 3900 1019  65.8  68.4  36.8  54  Steroid  I 21  58 F  PSS  3  3 ＋ ＋ ＋ 5600 496 42.0  63.0  98.0  35.6  3  Steroid  N 22  56 F  PSS  3  3 ＋ ＋ ＋ 10700 520 47.0 104.0  81.5  28.4  6  Steroid＋CPM  N 23  71 F  SjS  2  1 － ＋ ＋ 5500 506 58.0  60.2  81.6  38.8  91  Steroid  I 24  59 F  SjS  3  2 ＋ ＋ － 6300 404 57.3  61.8  71.6  47.7  20  Steroid  I
 
3＝many myoﬁbroblastic foci, 2＝some myoﬁbroblastic foci in parts, 1＝only focal myoﬁbroblastic foci, 0＝no myoﬁbroblastic foci, CPM＝
cyclophosphamide, I＝improve, N＝no changed, D＝death
 
Table 2  Myoﬁbroblasts in ﬁbrosing areas
 
Appearance of myoﬁbroblasts
 
Positive  Negative
 
Idiopathic NSIP(13) 7  6 CVD-NSIP(11) 10  1
 
P＜0.05
 
Table 3  Myoﬁbroblasts in intraalveolar organization
 
Intraalveolar organization positive
 
Appearance of myoﬁbroblasts
 
Positive  Negative
 
Idiopathic NSIP(9/13) 2  7 CVD-NSIP(10/11) 10  0
 
P＜0.001
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in clinical symptoms, laboratory data, or BALF cell fractions between the two, with no variation in respon-
siveness to treatment or prognosis. Pathologically, we noted a signiﬁcant diﬀerence in the presence or absence of myoﬁbroblasts in the ﬁbrosing areas and in the intra-
alveolar organization.
Myoﬁbroblasts develop several ultrastructural and biochemical features of smooth muscle cells, including the presence of microﬁlament bundles and the expression of
α-SMA, the actin isoform present in smooth muscle cells. Myoﬁbroblasts have been suggested to play a role in wound contraction and in the retractile phenomena observed during ﬁbrotic diseases. The existence of myoﬁbroblasts in human lung disease, as well as in animal models of airway and interstitial disease, has been recog-
nized for some time［15］. Mitchell et al. were the ﬁrst to demonstrate that these cells often contain SMA［16］.
For example, in bleomycin-induced ﬁbrosis in the rat,
predominant SMA antibody reactivity is observed in areas of parenchymal damage within days of bleomycin instilla-
tion［15, 16］. SMA-positive myoﬁbroblasts also occur in other forms of lung disease, including hypersensitivity pneumonitis, BOOP, and IPF［17］. Myoﬁbroblasts play important roles in the remodeling in pulmonary ﬁbrosis. Following pulmonary injury or inﬂammation,
myoﬁbroblasts diﬀerentiate from ﬁbroblasts and migrate from intra-alveolar septa into alveoli, where they produce collagen on stimulation by growth factors, with remod-
eling to ﬁbrosis［10-13］. Our previous study showed that in IPF which is pathologically diagnosed as UIP,
less proliferation of myoﬁbroblasts occurs than in RA-IP
［14］. In the present study, myoﬁbroblasts were appar-
ent in intra-alveolar organization in all cases of CVD-
NSIP, but in only 2 cases of idiopathic NSIP out of 9.
Thus, the background for the induction of myoﬁbroblasts allowing ﬁbrosis to progress diﬀers in CVD-NSIP and idiopathic NSIP. This result may also be in line with the previous ﬁndings that IIP diﬀers from interstitial pneumo-
nia associated with collagen vascular disease in terms of the mechanisms underlying ﬁbrosis.
We previously found a correlation between the pres-
ence or absence of myoﬁbroblasts in intra-alveolar organi-
zation and responsiveness to steroids in cases of BOOP
［18］. This is analogous to the relationship between the presence or absence of myoﬁbroblasts in intra-alveolar organization and resistance to treatment in cases of idiopathic NSIP. Therefore,with some types of IIP, the presence or absence of myoﬁbroblasts in intra-alveolar
 
organization might be associated with responsiveness to therapy. However, there is a possibility that patients with idiopathic NSIP who are positive for myoﬁbroblasts in intra-alveolar organization may develop collagen disease in the future, and we therefore need to follow these patients carefully. Moreover, this relationship between the pres-
ence of myoﬁbroblasts and the eﬀect of therapy was not indicated in the CVD-NSIP cases.
On the basis of previous studies of myoﬁbroblasts in ﬁbroblast foci in IPF, pulmonary ﬁbrosis is considered to begin with intra-alveolar ﬁbrosis［2, 19］. In NSIP,
however, the foci of ﬁbrosis do not match the prolifera-
tion of myoﬁbroblasts in intra-alveolar organization. This observation makes it diﬃcult to conclude that interstitial ﬁbroblasts have inﬁltrated into the intra-alveolar organiza-
tion, which may have been formed by a diﬀerent mecha-
nism in NSIP. Moreover, it is possible that the forma-
tion of intra-alveolar organization in idiopathic NSIP and CVD-NSIP is completely diﬀerent. In any case, it is evident from observations in cases of BOOP alone that a better response to steroids is achieved in cases where myoﬁbroblasts fail to appear in intra-alveolar organization.
This is an interesting ﬁnding, which is also worth bearing in mind when considering the formation of intra-alveolar organization.
The causes of the diﬀerences in the presence of myoﬁbroblasts in NSIP remains unclear. However,
several factors, such as transforming growth factor beta
(TGF-β)and platelet derived growth factor(PDGF), are reported to inﬂuence cell proliferation and the growth of myoﬁbroblasts. TGF-βinducesαsmooth muscle actin expression in ﬁbroblasts, so that they acquire the myoﬁbroblast phenotype. TGF-β is expressed at signiﬁcantly high levels in lung ﬁbrosis［10, 11, 20-22］.
PDGF is also reported to have mitogenic eﬀects on cells,
including myoﬁbroblasts, with importance emphasized in ﬁbroproliferative disease［12, 23, 24］. If the type or amounts of these factors diﬀer between idiopathic NSIP and CVD-NSIP, this might explain the variation in appearance of the myoﬁbroblasts found in this study.
Further investigation of these factors is necessary to clarify the role of myoﬁbroblasts in the remodeling of NSIP or other pulmonary ﬁbrosis.
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